Avatrombopag
Avatrombopag is a pharmaceutical drug with 37 clinical trials. Currently 6 active trials ongoing. Historical success rate of 84.6%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
18
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
68.8%
11 of 16 finished
31.3%
5 ended early
6
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Avatrombopag vs. Placebo for CIT in GI Malignancies
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
The Holistic Study
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Clinical Trials (37)
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Avatrombopag vs. Placebo for CIT in GI Malignancies
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
The Holistic Study
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
Avatrombopag for Chemotherapy-induced Thrombocytopenia
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA
Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
Avatrombopag Combined With IST as First-line Treatment for SAA
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37